Research Project
10374660
Project Summary/Abstract The Accelerating Medicines Partnership (AMP) program is a public private partnership started in 2014 to transform the way diagnostics and treatments are developed. Partners work together to increase the number of diagnostics and therapies while reducing the cost of development in several disease areas. The program uses an open science paradigm to support early, iterative integration of resources and evaluation of findings across multiple independent teams. In the AMP in Alzheimer?s Disease Target Discovery and Preclinical Validation project (AMP-AD) this open approach was designed to improve observations through integration of multiple data sources, to increase confidence in outcomes through transparency, reproducibility, and benchmarking of methods and to accelerate evaluation of nominated AD targets by aggregating evidence and expertise across the field. Cross-consortium activities are supported by the Data Coordination Center (DCC) led by Sage Bionetworks. Functions include resource sharing, providing analytical workspaces for researchers to perform cross-team analytical projects, and coordinated evaluation across the program of research outcomes. This supplement is designed to extend the activities of the AMP-AD DCC to support the AMP Autoimmune disorders of rheumatoid arthritis and systemic lupus erythematosus (SLE) (AMP-RA/SLE).
